Briefly, CMS1 subtype (“immune subtype”, 14% of CRC tumors) is characterized by a high TMB and MANA load, high immune infiltration, T helper 1 (Th1) signaling, BRAFV600E mutations, and an overexpression of immune checkpoint molecules such as PD-1, Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4), and Indoleamine 2,3-Dioxygenase 1 (IDO1). The gene discussed is CTLA4; the disease is colorectal carcinoma.